$RVPH News

Last published 15h ago

15h agoRVPHReviva Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission -
3mo agoRVPHReviva Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new
4mo agoRVPHReviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24thGlobeNewswireCUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek
5mo agoRVPHReviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company ShowcaseGlobeNewswireCUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to
6mo agoRVPHReviva Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in
6mo agoRVPHReviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric IndicationsGlobeNewswireCUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to
7mo agoRVPHReviva Announces Letter to ShareholdersGlobeNewswireCUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to
7mo agoRVPHReviva Reports Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswire- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package highlights well-tolerated
7mo agoRVPHReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingGlobeNewswireCUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
10mo agoRVPHReviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in SchizophreniaGlobeNewswireFindings reinforce brilaroxazine's treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also
10mo agoRVPHReviva to Present at the Sachs 9th Annual Neuroscience Innovation ForumGlobeNewswireCUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
10mo agoRVPHReviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of SchizophreniaGlobeNewswireWritten feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of
12mo agoRVPHReviva Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted
1y agoRVPHReviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025GlobeNewswireCUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary FibrosisGlobeNewswire- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel
1y agoRVPHReviva to Participate in the Spartan Capital Securities Second Annual Investor ConferenceGlobeNewswireCUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025GlobeNewswireCUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global PartnersGlobeNewswireCUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the 4th Annual Roth Healthcare Opportunities ConferenceGlobeNewswireCUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the Lytham Partners Fall 2025 Investor ConferenceGlobeNewswireCUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public OfferingGlobeNewswireCUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingGlobeNewswireCUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two
1y agoRVPHReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingGlobeNewswireCUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingGlobeNewswireCUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceGlobeNewswireCUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaGlobeNewswire– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – –
1y agoRVPHReviva to Participate in Upcoming Investor Conferences in May 2025GlobeNewswireCUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical
1y agoRVPHReviva to Participate in the A.G.P. Healthcare Company ShowcaseGlobeNewswireCUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the Citizens Life Sciences ConferenceGlobeNewswireCUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual MeetingGlobeNewswireCUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Reports Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for
1y agoRVPHReviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS CongressGlobeNewswireCUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas
1y agoRVPHReviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireCUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the 2025 BIO CEO & Investor ConferenceGlobeNewswireCUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva to Participate in the Lytham Partners 2025 Investor Healthcare SummitGlobeNewswireCUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoAPLT RVPH VSTMApplied Therapeutics Appoints John H. Johnson as Executive ChairmanGlobeNewswireShoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT),
1y agoRVPHReviva Announces Pricing of $18.0 Million Public Offering of Common Stock and WarrantsGlobeNewswireCUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Announces Proposed Public OfferingGlobeNewswireCUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
1y agoRVPHReviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in SchizophreniaGlobeNewswire– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – –
1y agoRVPHReviva Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and
2y agoRVPHReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaGlobeNewswire– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial
2y agoRVPHReviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024GlobeNewswireCUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
2y agoRVPHReviva to Participate in the UBS Global Healthcare ConferenceGlobeNewswireCUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
2y agoRVPHReviva to Participate in the 2024 Maxim Healthcare Virtual SummitGlobeNewswireCUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
2y agoRVPHReviva to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireCUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
2y agoRVPHReviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor ConferenceGlobeNewswireCUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet
2y agoRVPHReviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaGlobeNewswire– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia – – Additional vocal biomarker data
2y agoRVPHReviva to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireCUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet